No profile data available.
Compass Therapeutics, Inc. (CMPX) is a healthcare company in the additional cancer treatment drugs industry, based in Boston, United States, with about 39 full-time employees.
It reported revenue of $0 for fiscal year 2025, down 100.0% from fiscal year 2024, and net income of -$66.49 million. In Q2 2026 (the quarter ended June 30, 2026) revenue was $0. Its market capitalization was $178.83 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
, a clinical-stage oncology-focused biopharmaceutical company, develops antibody-based therapeutics for the treatment of various human diseases in the United States.
Compass Therapeutics reported $0 in revenue for fiscal year 2025, down 100.0% from $850,000 in fiscal year 2024. In Q2 2026 revenue was $0.
$178.83 million as of October 9, 2026.
Listed companies of a similar size in the same industry (additional cancer treatment drugs) include Corbus Pharmaceuticals Holdings, Inc. (CRBP), Adagene Inc. (ADAG), Innate Pharma S.a. (IPHA), ALX Oncology Holdings Inc. (ALXO).